A

Amgen

Makes biotech medicines for serious illnesses

Engineer – Process Development - Commissioning, Qualification, And Validation

Full-TimePosted on 10/19/2026
$88.3k - $119.4k/yr+ Discretionary annual bonus + Stock-based long-term incentives
Mid
Bachelor's, Master's, Associate's
New Albany, OH, USA
In PersonOn-site in New Albany, Ohio; approximately 20% travel.
Biology & BiotechRegulatory & Quality (Life Sciences)

About the job

Requirements
  • A master's degree, or a bachelor's degree and 2 years in a GMP-regulated environment, or an associate's degree and 6 years in a GMP-regulated environment, or a high school diploma/GED and 8 years in a GMP-regulated environment.
  • Understand combination product assembly technologies, automated and semi-automated equipment, and packaging operations.
  • Have experience supporting commissioning, qualification, and validation activities, including protocol writing, execution, and data analysis.
  • Have written and verbal communication skills and the ability to work in a team environment.
  • Demonstrate the ability to contribute to cross-functional technical projects.
  • Have experience working with manufacturing equipment suppliers.
  • Be able to learn rapidly in a complex, fast-moving GMP environment.
  • Bring a positive, development-oriented attitude.
Responsibilities
  • Complete commissioning activities and author and implement IQ/OQ/PQ protocols, validation plans, and lifecycle documentation.
  • Maintain the validated state of equipment and processes through periodic review and documentation updates.
  • Participate in equipment and system design reviews, supporting requirements definition and alignment of commissioning, qualification, and validation strategy.
  • Support and participate in factory acceptance testing, site acceptance testing, equipment installation, and startup readiness.
  • Collect and analyze process and equipment data to support validation, characterization, and sustained performance.
  • Support technical transfer of final drug product and combination product processes into the Amgen Ohio site, ensuring commissioning, qualification, and validation deliverables are met.
  • Perform data collection and process characterization to support new equipment and process introductions.
  • Troubleshoot device assembly and packaging equipment using engineering fundamentals and multifunctional support.
  • Provide technical feedback on change control, deviations, corrective and preventive actions, and risk assessments as applicable to validation activities.
  • Support commissioning, qualification, and validation project planning, schedule alignment, and execution for new or modified equipment and systems.
  • Partner with Manufacturing, Process Development, Engineering, and Quality to ensure project deliverables are met on time.
  • Maintain communication with site teams and the broader company network to align on technical deliverables.
  • Support documentation reviews, supplier interactions, and internal readiness for inspections or audits.
  • Serve as a technical resource for automated and semi-automated device assembly and packaging equipment.
  • Support and lead investigations into technical issues affecting equipment performance or reliability.
  • Review vendor documentation, test protocols, and engineering drawings for compliance with commissioning, qualification, and validation requirements.
  • Evaluate equipment and process performance trends to identify improvement opportunities.
  • Identify and support improvements in throughput, reliability, and process capability across packaging and assembly operations.
  • Participate in Lean, Six Sigma, and Operational Excellence initiatives to strengthen equipment performance and commissioning, qualification, and validation processes.
  • Support data-driven decision-making through process monitoring, trend analysis, and equipment performance assessments.
  • Recommend enhancements to commissioning, qualification, and validation procedures, templates, and standard methodologies to increase efficiency and compliance.
  • Build collaborative relationships with site Process Development, Manufacturing and Quality Assurance, Engineering and Maintenance, global technical and validation networks, and external equipment suppliers.
  • Leverage collaborative relationships to support equipment qualification, technical troubleshooting, validation standardization, and performance trending.
Desired Qualifications
  • Have exposure to Lean or Six Sigma as part of an Operational Excellence mindset.

About the company

Amgen develops and makes biologic medicines, which are drugs built from proteins and antibodies grown in living cells, for serious conditions such as heart disease, cancer, and bone loss. Its anemia drug Epogen, approved in 1989, became one of the biotechnology industry's first blockbuster medicines. Amgen grows these drugs in large tanks called bioreactors, and its products include the cholesterol drug Repatha, the bone-building drug Evenity, and the severe asthma drug Tezspire. It earns money by selling these medicines, mostly through large drug wholesalers that supply hospitals and pharmacies. Amgen was founded in 1980 and is based in Thousand Oaks, California.

Company Size

10,001+

Company Stage

IPO

Headquarters

Thousand Oaks, California

Founded

1980

Get referred to Amgen

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Growth is broad-based: 22 products grew at least 10%, lifting June 2026 quarter revenue 10% to $10.1 billion.
  • Stock grants gained value: Amgen shares rose 27% from January to October 9, 2026, versus 10% for rival Eli Lilly.
  • Many U.S. roles are remote: 145 of Amgen's 615 U.S. job openings in October 2026 were fully remote.

What critics are saying

  • Its 2025 best seller is shrinking: cheaper copies cut bone drug Prolia's sales 32% in the June 2026 quarter.
  • MariTide, Amgen's obesity bet, faces a giant: Lilly's Mounjaro and Zepbound outsold all of Amgen in the June 2026 quarter.
  • Most tech openings are in India: 156 of Amgen's 210 information systems jobs in October 2026 were in Hyderabad.

What makes Amgen unique

  • It copies rivals' blockbusters too: Pavblu, its version of Regeneron's eye drug Eylea, sold $700 million in 2025.
  • Amgen hunts drug targets in a nation's DNA: its Icelandic unit deCODE has genetic data on two-thirds of Iceland's adults.
  • Amgen opened a U.S. cancer-drug class: Blincyto, approved in 2014, was the first to tether immune cells to cancer.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Professional Development Budget
  • Conference Attendance Budget

Company News

Yahoo Finance
Oct 22nd, 2026
Eli Lilly vs Amgen: $65.2B revenue and 45% growth against a cheaper stock for 2026

Eli Lilly is growing far faster than Amgen, but investors pay a steep premium for it. The article's author favours Lilly for long-term investors in 2026. Lilly's FY 2025 revenue rose 45% to about $65.2 billion, with net income of $20.6 billion and a 32% net margin. Amgen's revenue grew about 10% to $36.7 billion, with net income of $7.7 billion and a 21% margin. Lilly trades at a forward P/E of 38.3x against Amgen's 19.4x. Its debt-to-equity ratio is about 1.6x, compared with nearly 6.3x for Amgen. Lilly's growth rests on its GLP-1 drugs Zepbound and Mounjaro. The article projects 2026 revenue of $88.7 billion, against about $37.8 billion for Amgen.

Yahoo Finance
Oct 21st, 2026
Amgen's focus shifts to six growth drivers and MariTide as rare disease sales hit $1.6B

Amgen now frames its story around six key growth drivers, which grew 26% from a year earlier in fiscal Q2 2026 and made up nearly 70% of product sales. Rare disease, once reported on its own, is one of the six. The rare disease portfolio grew 21% to $1.6 billion, about 16% of quarterly revenue. Total revenue rose 9.5%, and management raised its 2026 revenue guidance to between $38.2 billion and $39.4 billion. Management also highlighted MariTide, an obesity drug in Phase III trials. Amgen wants it to be the first monthly or less frequent obesity therapy and is already scaling up manufacturing. One risk sits in rare disease. On September 1, 2026, Britain's medicines regulator suspended Tavneos for new patients, citing an unreliable main study. The drug made $119 million in fiscal Q1 2026. Amgen's next report is expected around November 3, 2026.

Yahoo Finance
Oct 20th, 2026
Johnson & Johnson and Amgen beat the market in 2026, but can the dividend stocks keep going?

Johnson & Johnson and Amgen, two dividend stocks that have beaten the broader market this year, could suit investors bracing for a possible crash. J&J's latest quarter beat expectations, and it slightly raised its 2026 guidance. But its medtech unit is struggling, as demand for the Impella heart pump has fallen amid safety questions and a US Class 1 recall. Long-term, it has new drugs, a robotic surgery system approved in the US, and a proposed $5.5 billion talc settlement. It is a Dividend King with 64 straight years of payout increases. Amgen's second-quarter revenue rose 10% to $10.1 billion, despite pressure on Tavneos and falling denosumab sales. It has raised payouts 152% over a decade and offers a 2.3% forward yield, against 1.1% for the S&P 500.

Yahoo Finance
Oct 17th, 2026
Amgen raises 2026 revenue forecast to $38.8B as shares gain 15.2%

Amgen raised its fiscal 2026 revenue forecast on August 4 to $38.8 billion at the midpoint, up 2.6% from $37.8 billion. Adjusted earnings per share guidance rose to $22.90 from $22.40. Six key growth drugs grew 26% from a year earlier and made up nearly 70% of product sales in the June quarter. Repatha sales rose 37% to $953 million, offsetting a 33% drop in Prolia and XGEVA sales as biosimilar copies launched. Total revenue rose 10%. The stock has gained 15.2% since the release, against 1.9% for the S&P 500. It closed at $434.03 on October 15, above both its 50-day and 200-day averages. Reaching the midpoint requires $20.1 billion in the second half. Amgen's next report is expected around November 3.

Yahoo Finance
Oct 8th, 2026
Amgen invests $2.6B in manufacturing for MariTide obesity drug ahead of Phase III results

Amgen is testing MariTide, an experimental obesity drug designed to be dosed monthly or less frequently. The therapy has advanced into late-stage Phase III trials, with nine studies currently running and three more planned. Executives reported strong enrolment during the company's second-quarter 2026 earnings call on 4 August 2026. Amgen expects capital spending of about $2.6 billion in 2026, partly to scale manufacturing capacity for MariTide's eventual launch. The company is investing across its US manufacturing sites in North Carolina, Ohio, and Puerto Rico. Amgen stock has returned 44% over the past twelve months, outpacing the S&P 500's 17.1% gain. The company reported $38.1 billion in revenue over the last twelve months, up from $34.9 billion a year earlier.